Abstract Number: 0748 • ACR Convergence 2024
Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica
Background/Purpose: Treatment of polymyalgia rheumatica (PMR) is hindered by lack of glucocorticoid (GC)-sparing therapies with proven efficacy. A retrospective study showed a higher proportion of…Abstract Number: 1637 • ACR Convergence 2024
Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome
Background/Purpose: The dysregulation of the immune system inherent in inflammatory diseases may contribute to the development of neoplasms. However, the relationship between the giant cell…Abstract Number: 0755 • ACR Convergence 2024
Characteristics Associated with Long-Term Glucocorticoids Use in Patients with New Onset Polymyalgia Rheumatica
Background/Purpose: Polymyalgia rheumatica (PMR), a common inflammatory rheumatic condition in people aged ≥50 years, is primarily treated with glucocorticoids (GC). Extended GC therapy can increase…Abstract Number: 1697 • ACR Convergence 2024
Results of a One Year Randomized Double-Blind Placebo-Controlled Trial with Methotrexate 25mg Per Week for Recently Diagnosed PolyMyalgia Rheumatica
Background/Purpose: The most effective treatment for Polymyalgia rheumatica (PMR) are glucocorticoids (GC), but these are associated with toxicity. Three randomized controlled trials (RCTs) suggest methotrexate…Abstract Number: 0267 • ACR Convergence 2023
Variations in Approach to the Diagnosis and Management of Polymyalgia Rheumatica Among Australian Rheumatologists
Background/Purpose: Polymyalgia rheumatica (PMR) is the second-most common inflammatory rheumatic disease but there remains variation amongst rheumatologists in approaches to diagnosis and management. This study…Abstract Number: 1878 • ACR Convergence 2023
MRI-determined Intramuscular Fat Changes During Oral Glucocorticoid Treatment: Findings from a Feasibility Study
Background/Purpose: Oral glucocorticoid therapy has many adverse effects including insulin resistance and myopathy. Long-term glucocorticoid therapy causes a "sarcopenic obesity" phenotype of adiposity with muscle…Abstract Number: 0717 • ACR Convergence 2023
Mitochondria-mediated Platelet Activation in Polymyalgia Rheumatica
Background/Purpose: Platelets have been suggested to be involved in polymyalgia rheumatica (PMR) pathogenesis with elevated platelet activation observed in early stages of the disease. Upon…Abstract Number: 1890 • ACR Convergence 2023
Use of Artificial Intelligence to Diagnose Polymyalgia Rheumatica on 18F-FDG Whole Body PET/CT in Patients with Atypical Clinical Features
Background/Purpose: PET/CT is a highly sensitive and specific test for diagnosing PMR.(1) This study investigated the utility of 18F-FDG whole body PET/CT in patients presenting…Abstract Number: 0718 • ACR Convergence 2023
Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids in a Real-World Setting
Background/Purpose: The burden of continuing glucocorticoids (GCs) in patients with polymyalgia rheumatica (PMR) who have an inadequate response (IR)to GCs has not been evaluated.Methods: An…Abstract Number: 2392 • ACR Convergence 2023
Characterization of Arterial Dendritic Cells in Polymyalgia Rheumatica and Giant Cell Arteritis
Background/Purpose: Polymyalgia rheumatica (PMR) is associated with giant cell arteritis (GCA) in 16 to 21% of cases. This raises the question of a pathophysiological continuum…Abstract Number: 0719 • ACR Convergence 2023
Polymyalgia Rheumatica Following SarsCOV-2 Vaccination: A Single Center Cohort Study
Background/Purpose: Polymyalgia rheumatica (PMR) incidence peaks in individuals between 70 and 80 years of age; this same group is also at increased risk of complications…Abstract Number: 2393 • ACR Convergence 2023
CXCL9/IL-6 and MMP3/CD141 Ratio Allow to Discriminate Between Isolated PMR and GCA/PMR Overlap
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are frequently overlapping conditions. It is estimated that 16 to 21% of PMR patients have GCA.…Abstract Number: 0720 • ACR Convergence 2023
Cognitive Function and Its Associated Factors in Polymyalgia Rheumatica
Background/Purpose: Over the past decade our understanding of the prevalence, and indeed impact of cognitive impairment in rheumatic diseases has increased. Intact cognitive function is…Abstract Number: 2395 • ACR Convergence 2023
Recommendations for Early Referral of Patients with Suspected Polymyalgia Rheumatica: An Initiative from the International Giant Cell Arteritis and Polymyalgia Rheumatica Study Group
Background/Purpose: Existing EULAR/ACR guidelines on polymyalgia rheumatica (PMR) are focused on the management by rheumatologists. However, there is no consensus regarding early referral and evaluation…Abstract Number: 0721 • ACR Convergence 2023
Characterization of Numeric Rating Scales for Symptom Assessment in Polymyalgia Rheumatica
Background/Purpose: Pain, stiffness, and fatigue have been defined as core assessment domains in polymyalgia rheumatica (PMR) by the OMERACT PMR Working Group (PMRWG). Patient partners…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 7
- Next Page »